Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis

Journal of Cellular and Molecular Medicine

Volumn 21, Issue 9, 2017, Pages 1815-1825

  Yan, Jian Jun ^a   Lu, Ying ^b   Kuai, Zheng Ping ^c   Yong, Yong Hong ^b  

^a THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

copeptin; heart failure; meta analysis

Indexed keywords

COPEPTIN; GLYCOPEPTIDE;

ARTICLE; BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL HETEROGENEITY; CORONARY ARTERY DISEASE; FOLLOW UP; HEART FAILURE; HUMAN; META ANALYSIS; NEWCASTLE-OTTAWA SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; ADULT; AGED; BLOOD; FEMALE; MALE; MIDDLE AGED; MORTALITY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLYCOPEPTIDES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 85014170714     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13102     Document Type: Article

References (45)

1. Singh Ranger G. The physiology and emerging roles of antidiuretic hormone. Int J Clin Pract. 2002; 56: 777–82.
2. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005; 95: 8B–13B.
3. Robertson GL, Mahr EA, Athar S, et al. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973; 52: 2340–52.
4. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52: 112–9.
5. Fiore G, Suppress P, Triggiani V, et al. Neuroimmune activation in chronic heart failure. Endocr Metab Immune Disord Drug Targets. 2013; 13: 68–75.
6. Giannopoulos G, Deftereos S, Panagopoulou V, et al. Copeptin as a biomarker in cardiac disease. Curr Top Med Chem. 2013; 13: 231–40.
7. Wells GA, Shea A, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–88.
9. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychol Methods. 2001; 6: 203–17.
10. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992; 135: 1301–9.
11. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J. 2006; 6: 40–57.
12. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629–34.
13. Reinstadler SJ, Klug G, Feistritzer HJ, et al. Long-term predictive value of copeptin after acute myocardial infarction: a cardiac magnetic resonance study. Int J Cardiol. 2014; 172: e359–60.
14. Melenovsky V, Kotrc M, Polak J, et al. Availability of energetic substrates and exercise performance in heart failure with or without diabetes. Eur J Heart Fail. 2012; 14: 754–63.
15. Benes J, Kotrc M, Borlaug BA, et al. Resting heart rate and heart rate reserve in advanced heart failure have distinct pathophysiologic correlates and prognostic impact: a prospective pilot study. JACC Heart Fail. 2013; 1: 259–66.
16. Reinstadler SJ, Klug G, Feistritzer HJ, et al. Association of copeptin with myocardial infarct size and myocardial function after ST segment elevation myocardial infarction. Heart. 2013; 99: 1525–9.
17. Vetrone F, Santarelli S, Russo V, et al. Copeptin decrease from admission to discharge has favorable prognostic value for 90-day events in patients admitted with dyspnea. Clin Chem Lab Med. 2014; 52: 1457–64.
18. Peacock WF, Nowak R, Christenson R, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011; 18: 947–58.
19. Potocki M, Breidthardt T, Mueller A, et al. Copeptin and risk stratification in patients with acute dyspnea. Crit Care. 2010; 14: R213.
20. Maisel A, Xue Y, Shah K, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011; 4: 613–20.
21. Dieplinger B, Gegenhuber A, Haltmayer M, et al. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart. 2009; 95: 1508–13.
22. Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006; 36: 771–8.
23. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007; 115: 2103–10.
24. Miller WL, Grill DE, Struck J, et al. Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure. Am J Cardiol. 2013; 111: 880–5.
25. Miller WL, Hartman KA, Grill DE, et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart. 2012; 98: 389–94.
26. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008; 52: 266–72.
27. Neuhold S, Huelsmann M, Strunk G, et al. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem. 2010; 56: 121–6.
28. Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Cardiac Fail. 2008; 14: 739–45.
29. Smith JG, Newton-Cheh C, Almgren P, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010; 56: 1712–9.
30. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012; 125: 233–40.
31. Wannamethee SG, Welsh P, Whincup PH, et al. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study. Eur J Heart Fail. 2014; 16: 25–32.
32. O'Malley RG, Bonaca MP, Scirica BM, et al. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36). J Am Coll Cardiol. 2014; 63: 1644–53.
33. Alehagen U, Dahlstrom U, Rehfeld JF, et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011; 305: 2088–95.
34. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Cardiac Fail. 2007; 13: 42–9.
35. Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011; 13: 726–33.
36. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009; 30: 1187–94.
37. Balling L, Kistorp C, Schou M, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Cardiac Fail. 2012; 18: 351–8.
38. Bosselmann H, Egstrup M, Rossing K, et al. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. Int J Cardiol. 2013; 170: 202–7.
39. Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010; 12: 338–47.
40. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009; 116: 257–63.
41. Bolignano D, Cabassi A, Fiaccadori E, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014; 52: 1447–56.
42. Mason JM, Hancock HC, Close H, et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS ONE. 2013; 8: e53560.
43. Bahrmann P, Bahrmann A, Hofner B, et al. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department. Eur Heart J Acute Cardiovasc Care. 2015; 4: 137–47.
44. Oghlakian G, Klapholz M. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev. 2009; 17: 10–5.
45. Fan YH, Zhao LY, Zheng QS, et al. Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. Life Sci. 2007; 81: 327–35.